Published in Ann Neurol on August 01, 2002
Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol (2004) 5.29
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement (2006) 1.34
Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med (2010) 1.27
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol (2007) 1.15
The isoprostanes--25 years later. Biochim Biophys Acta (2014) 1.11
Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxid Med Cell Longev (2014) 0.97
Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int J Cell Biol (2012) 0.96
Metabolic multianalyte microphysiometry reveals extracellular acidosis is an essential mediator of neuronal preconditioning. ACS Chem Neurosci (2012) 0.91
Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener (2007) 0.88
Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases. Oxid Med Cell Longev (2014) 0.88
Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. NeuroRx (2006) 0.87
Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder. Oxid Med Cell Longev (2013) 0.86
Eicosapentaenoic-acid-derived isoprostanes: synthesis and discovery of two major isoprostanes. Bioorg Med Chem Lett (2008) 0.86
Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment. Biomed Res Int (2014) 0.83
Blood markers of oxidative stress in Alzheimer's disease. J Cell Mol Med (2012) 0.83
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis (2010) 0.82
Current status of biomarker research in neurology. EPMA J (2016) 0.79
Plasma F2-isoprostane level and cognitive function over eight years in non-demented older adults: Findings from the Health ABC Study. Prostaglandins Leukot Essent Fatty Acids (2010) 0.76
Acupuncture mechanism and redox equilibrium. Evid Based Complement Alternat Med (2014) 0.75
Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep (2011) 0.75
Peripheral biomarkers of oxidative damage in Alzheimer's disease. Ann Neurol (2003) 0.75
Vitamin C acts as a hepatoprotectant in carbofuran treated rat liver slices in vitro. Toxicol Rep (2017) 0.75
Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A (2004) 12.89
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med (2011) 3.58
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med (2013) 3.30
A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One (2008) 3.25
Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J (2004) 3.15
Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med (2006) 3.04
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Isoprostanes: markers and mediators of oxidative stress. FASEB J (2004) 2.83
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol (2002) 2.70
The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62
Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc (2007) 2.56
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med (2002) 2.17
Factors associated with oxidative stress in human populations. Am J Epidemiol (2002) 2.13
Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc (2008) 2.13
Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol (2005) 2.12
Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem (2002) 2.11
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol (2007) 1.98
Unobtrusive assessment of activity patterns associated with mild cognitive impairment. Alzheimers Dement (2008) 1.95
Uric acid as a CNS antioxidant. J Alzheimers Dis (2010) 1.93
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension (2006) 1.91
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics (2009) 1.82
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation (2005) 1.82
Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension (2005) 1.80
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Oxidant injury occurs rapidly after cardiac arrest, cardiopulmonary resuscitation, and reperfusion. Crit Care Med (2005) 1.76
Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem (2005) 1.73
An electronic pillbox for continuous monitoring of medication adherence. Conf Proc IEEE Eng Med Biol Soc (2006) 1.72
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem (2006) 1.70
Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res (2005) 1.70
Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res (2004) 1.68
Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology (2012) 1.66
Human biochemistry of the isoprostane pathway. J Biol Chem (2008) 1.63
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke (2004) 1.63
Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A (2002) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 1.62
Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol (2006) 1.62
Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. J Biol Chem (2004) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest (2015) 1.55
The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008) 1.55
Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition. Brain Behav Immun (2006) 1.54
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res (2003) 1.53
The inhibitory effect of manganese on acetylcholinesterase activity enhances oxidative stress and neuroinflammation in the rat brain. Toxicology (2011) 1.51
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol (2005) 1.49
Vitamin E and immunity after the Kona Triathlon World Championship. Med Sci Sports Exerc (2004) 1.47
Reduction in glutathione peroxidase 4 increases life span through increased sensitivity to apoptosis. J Gerontol A Biol Sci Med Sci (2007) 1.47
Cognitive impairment risk: white matter hyperintensity progression matters. Neurology (2009) 1.46
Mass spectrometric quantification of F2-isoprostanes as indicators of oxidant stress. Methods Mol Biol (2002) 1.45
F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers (2005) 1.44
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem (2003) 1.44
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Radic Biol Med (2011) 1.42
Centralized oversight of physician-scientist faculty development at Vanderbilt: early outcomes. Acad Med (2008) 1.42
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Effects of age and caloric restriction on lipid peroxidation: measurement of oxidative stress by F2-isoprostane levels. J Gerontol A Biol Sci Med Sci (2005) 1.41
Isoprostane generation and function. Chem Rev (2011) 1.41
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis (2008) 1.40
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 1.39
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 1.39
Parkinson's disease is associated with hippocampal atrophy. Mov Disord (2003) 1.37